GSA Capital Partners LLP Buys 3,355 Shares of Annexon, Inc. (NASDAQ:ANNX)

GSA Capital Partners LLP boosted its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 10.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,581 shares of the company’s stock after acquiring an additional 3,355 shares during the quarter. GSA Capital Partners LLP’s holdings in Annexon were worth $205,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ANNX. Sandia Investment Management LP acquired a new position in Annexon in the second quarter valued at about $49,000. Victory Capital Management Inc. acquired a new stake in shares of Annexon in the second quarter valued at $51,000. Principal Financial Group Inc. acquired a new position in Annexon during the 2nd quarter worth about $56,000. Comerica Bank bought a new position in shares of Annexon in the first quarter worth about $72,000. Finally, ProShare Advisors LLC bought a new stake in shares of Annexon during the first quarter valued at approximately $87,000.

Insiders Place Their Bets

In other news, EVP Ted Yednock sold 5,500 shares of the stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $5.64, for a total value of $31,020.00. Following the completion of the sale, the executive vice president now owns 10,000 shares in the company, valued at $56,400. This represents a 35.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders sold 20,908 shares of company stock worth $135,768. 12.67% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Annexon in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Annexon in a research note on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $15.80.

Annexon Trading Down 0.6 %

NASDAQ ANNX opened at $5.14 on Monday. Annexon, Inc. has a 12 month low of $2.27 and a 12 month high of $8.40. The business’s 50-day moving average price is $6.79 and its two-hundred day moving average price is $5.94. The firm has a market capitalization of $547.87 million, a PE ratio of -4.90 and a beta of 1.23.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.